Plan-les-ouates, Switzerland
Plan-les-ouates, Switzerland

Time filter

Source Type

GENEVA, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Addex Therapeutics (SIX: ADXN) announced today the appointment of Roger G. Mills, M.D., to the newly created position of Chief Medical Officer. Dr. Mills brings more than 25 years of biopharmaceutical industry experience at both global pharmaceutical companies and biotechnology companies, including Acadia Pharmaceuticals, Pfizer, Gilead Sciences, Abbott Laboratories and Wellcome, across a spectrum of disease areas.  His extensive track record includes managing drug development programs from Investigational New Drug Application preparation through to post-marketing and OTC products, including NUPLAZID(TM) for the treatment of Parkinson's disease psychosis, as well as regulatory affairs and business development activities.  Most recently, Dr. Mills was with Acadia Pharmaceuticals for nine years, serving as Executive Vice President, Development and Chief Medical Officer.  In this role, he oversaw the largest ever international phase III program in Parkinson's disease psychosis, and led the Company's New Drug Application submission to the US Food and Drug Administration (FDA) for NUPLAZID, which was subsequently approved and remains the first and only medication approved by the FDA in this indication. "We are delighted to welcome Roger to the Addex team, he brings a unique blend of drug development expertise, commercial experience and US public biotechnology company operations knowledge," said Tim Dyer, CEO of Addex. "Roger's experience in helping to successfully and significantly grow Acadia will be invaluable to Addex as we continue to execute on our strategy to develop dipraglurant for levodopa-induced dyskinesia associated with Parkinson's disease." "I am excited to join Addex at such a critical juncture in the Company's corporate development," said Roger Mills. "Addex's development pipeline holds significant promise, and I look forward to applying my broad experience in the pharmaceutical industry and dealing with regulatory agencies to successfully advance the Company's product candidates." Dr. Mills currently serves as a Visiting Professor at the Centre for Age Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King's College London.  He received his medical degree from Imperial College, Charing Cross Hospital Medical School, London, UK. About Addex Therapeutics Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs.  Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


News Article | February 27, 2017
Site: globenewswire.com

Geneva, Switzerland, 27 February 2017 - Addex Therapeutics (SIX: ADXN) announced today the publication of a study demonstrating the anti-epileptic effects of ADX71149, a metabotropic glutamate receptor subtype 2 (mGlu2) positive allosteric modulator (PAM), given alone or in combination with the globally marketed antiseizure drug levetiracetam (LEV) in a preclinical model of epilepsy. These data, published in Epilepsia, the peer-reviewed journal of the international league against epilepsy (http://onlinelibrary.wiley.com/doi/10.1111/epi.13659/abstract), support the potential utility of ADX71149 to address treatment-resistant epilepsy. "These studies performed by our collaborator Janssen Pharmaceuticals, Inc. suggest there is a positive pharmacodynamic relationship or strong synergistic effect for ADX71149 and LEV when given in combination," said Robert Lütjens, Head of Discovery of Addex. "If this effect can be translated in the clinic, it will strongly support a rational polypharmacy concept in the treatment of epilepsy patients." The publication summarizes the effects obtained when the mGlu2 receptor is activated using an agonist or PAM, such as ADX71149, in the 6Hz psychomotor seizure test, considered to be the most relevant model of pharmacoresistant limbic seizures. In particular, the data show that while seizures are reduced when mGlu2-acting compounds are administered alone, their combination with LEV result in a potent reduction of doses required to produce full efficacy, which is important because higher doses of LEV are associated with dose-limiting side effects, such as aggression, nervousness/anxiety, somnolence and fatigue. In this study, a fixed dose of ADX71149 was seen to increase the potency of LEV, leading to an approximate 35-fold increase in its potency. Conversely, using a fixed dose of LEV with varying doses of ADX71149 resulted in an approximate 14-fold increase in ADX71149 potency. "The Janssen team has conducted outstanding research with mGlu2 PAMs and continue to validate the potential of ADX71149 in epilepsy," commented Tim Dyer, CEO of Addex. "Treatment-resistant epilepsy remains a high unmet medical need, with new avenues of treatment urgently needed. We are continuing to explore with Janssen how best to move ADX71149 into a Phase 2a proof of concept study." About Epilepsy and Levetiracetam (LEV): Epilepsy is one of the most common serious neurological disorders, affecting about 65 million people globally (Thurman et al. 2011). It affects 1% of the population by age 20 and 3% of the population by age 75 (Holmes et al. 2008). Epilepsy describes a condition in which a person has recurrent seizures due to a chronic, underlying process. It also refers to a clinical phenomenon rather than a single disease entity, since there are many forms and causes of epilepsy. Epilepsy is a disease of the brain defined by any of the following conditions: (1) at least two unprovoked (or reflex) seizures occurring more than 24 h apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an epilepsy syndrome (Fisher et al. 2014). The synaptic vesicle protein 2A (SV2A) has been identified as a broad spectrum anticonvulsant target in models of partial and generalized epilepsy, and studies in animal models and human tissue suggest that changes in the expression of SV2A are implicated in epilepsy (Mendoza-Torreblanca et al. 2013; Kaminski et al. 2012). SV2A ligands include levetiracetam (Lynch et al. 2004), which is an antiepileptic drug commercialized under trademark Keppra®, approved in Europe and USA as a monotherapy or add-on therapy in patients diagnosed with epilepsy. About ADX71149 and the Addex / Janssen Agreement: ADX71149 is a novel, first-in-class potent, oral, small molecule positive allosteric modulator (PAM) of metabotropic glutamate receptor 2 (mGluR2), a Family C class of G Protein Coupled Receptor (GPCR). The development of ADX71149 is part of a worldwide research collaboration and license agreement between Addex and Janssen Pharmaceuticals, Inc. to discover, develop and commercialize a novel mGluR2 PAM medication for the treatment of anxiety, schizophrenia and other undisclosed indications. Under the terms of the agreement, Addex is eligible for up to a total of €112 million in milestone payments based on potential development and regulatory achievements. In addition, Addex is eligible for low double-digit royalties on sales of any mGluR2 PAM medication developed under the agreement. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


Geneva, Switzerland, 28 February 2017 - Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.0 million through a private placement in which 1.5 million treasury shares were placed at CHF2 per share. The private placement was led by Herculis Partners SA. "We see significant value in Addex's pipeline and validated discovery platform, which we believe is not fully appreciated by the market," said Patrick Girod, Managing Partner of Herculis. "With their lead asset, dipraglurant, poised to begin registration trials in levodopa-induced-dyskinesia associated with Parkinson's disease, under the direction of their recently appointed and well regarded Chief Medical Officer, Roger Mills, we believe the Company is well-positioned to create substantial long-term shareholder value." "We have made great progress in advancing our pipeline of allosteric modulator drug candidates and leveraging our technology platform through collaborations with patient advocacy groups, government and academic institutions," said Tim Dyer, Chief Executive Officer of Addex. "These additional funds extend our cash runway through 2018 and allow us to continue to advance our pipeline in collaboration with these partners. We remain focused on securing the resources necessary to advance dipraglurant into registration trials for levodopa-induced-dyskinesia associated with Parkinson's disease, initiating a proof-of-concept study of dipraglurant in dystonia and advancing ADX71441 into Phase 1 studies." Financial Update Addex completed 2016 with cash and cash equivalents of CHF1.4 million (2015: CHF2.6 million). Following the reported sale of treasury shares, cash and cash equivalence currently total CHF3.9 million. About Addex Therapeutics Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


News Article | December 13, 2016
Site: globenewswire.com

Geneva, Switzerland, 13 December 2016 - Addex Therapeutics (SIX: ADXN), announced today that the pharmacological profile of ADX71441, gamma-aminobutyric acid subtype B (GABAB) receptor positive allosteric modulator (PAM), was published in Neuropharmacology, a leading peer reviewed journal. The pharmacological results published in Neuropharmacology (Kalinichev et al, 2017; available online) describe the PAM mode of action of ADX71441 on rat and human GABAB receptors, its pharmacokinetic parameters, as well as the effect obtained after oral administration in rodent models of anxiety (marble burying and elevated plus maze models), and visceral pain-associated behaviors (acetic acid-writhing model). Minimal effective dose observed in these models was 3 mg/kg, corresponding to 340-440 ng/ml of compound in the plasma. "ADX71441 is a first in class, Phase I-ready compound with a once-daily profile," said Robert Lutjens, head of discovery at Addex. "ADX71441's positive allosteric modulator pharmacological profile and absolute selectivity for the GABAB receptor make it potentially superior for indications that have been clinically validated by the orthosteric agonist, baclofen, such as addiction, chronic pain, anxiety, epilepsy, autism, Fragile X syndrome, psychosis, over active bladder, spasticity and CMT1A." About GABAB Activation and ADX71441 Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and used for overactive bladder (OAB), but is not more widely used due to a variety of side effects and rapid clearance, requiring frequent dosing. ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecules that has demonstrated excellent preclinical efficacy and tolerability in several rodent models of pain, anxiety, addiction and OAB and have also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 differs from the generic drug baclofen in that it is a positive allosteric modulator rather than an orthosteric agonist at the GABAB receptor. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists (May and Christopoulos 2003; Langmead and Christopoulos 2006; Perdona et al. 2011; Urwyler 2011; Gjoni et al., 2008; Ahnaou et al). About Addex Therapeutics Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs.  Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


News Article | December 10, 2016
Site: marketersmedia.com

— Stroke Pipeline Market Companies Involved in Therapeutics Development are AB Science SA, Acticor Biotech, ActiveSite Pharmaceuticals Inc, Addex Therapeutics Ltd, advanceCor GmbH, Affibody AB, Amarantus Bioscience Holdings Inc, Anavex Life Sciences Corp, Angion Biomedica Corp, Antoxis Ltd, APT Therapeutics, Inc., ArmaGen Inc, Asterias Biotherapeutics, Inc., AstraZeneca Plc, Athersys Inc, Bayer AG, Bioasis Technologies Inc, Biogen Inc, Boehringer Ingelheim GmbH, Cardax Inc, Cellular Biomedicine Group Inc, CHA Bio & Diostech Co Ltd, ContraVir Pharmaceuticals Inc, CSPC Pharmaceutical Group Limited, D-Pharm Ltd, Daiichi Sankyo Company Ltd, DiaMedica Inc, Diffusion Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Fina Biotech, Genervon Biopharmaceuticals LLC, Glialogix Inc, Glucox Biotech AB, Green Cross Corp, Huons Co Ltd, International Stem Cell Corp, Jeil Pharmaceutical Co Ltd, JN-International Medical Corp, Laboratoires Pierre Fabre SA, LegoChem Biosciences Inc, Les Laboratoires Servier SAS, Living Cell Technologies Ltd, Lumosa Therapeutics Co Ltd, M et P Pharma AG, Magnus Life Ltd, Mapreg SAS, Mast Therapeutics Inc, Medestea Research & Production SpA, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, Neuralstem Inc, Neuren Pharmaceuticals Ltd, Neurofx Inc, Neuronax SAS, Neurotec Pharma SL, NeuroVive Pharmaceutical AB, New Haven Pharmaceuticals, Inc., New World Laboratories Inc, NoNO Inc, NuvOx Pharma LLC, Omeros Corp, Panacea Pharmaceuticals Inc, PharmatrophiX, Inc., Pharmaxis Ltd, Pharmicell Co Ltd, Phoenix Biotechnology Inc, Phylogica Ltd, PhytoHealth Corp, Pluristem Therapeutics Inc, Primary Peptides, Inc., Q Therapeutics Inc, QR Pharma Inc, ReCyte Therapeutics Inc, Regenera Pharma Ltd, RegeneRx Biopharmaceuticals Inc, Remedy Pharmaceuticals Inc, ReNeuron Group Plc, SanBio Inc, Saneron CCEL Therapeutics Inc, Shin Poong PharmCo Ltd, Simcere Pharmaceutical Group, Stemedica Cell Technologies Inc, SynZyme Technologies LLC, Targazyme Inc, The International Biotechnology Center (IBC) Generium, TikoMed AB, vasopharm GmbH, Verseon Corp, Vicore Pharma AB, Virogenomics BioDevelopment Inc, WhanIn Pharmaceutical Co Ltd and Zocere Inc. This research provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774104 The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 10, 21, 14, 1, 89 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 35 and 4 molecules, respectively. Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774104 • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular). • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774104-stroke-pipeline-review-h2-2016.html


News Article | November 8, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression   ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Treatment Resistant Depression  - Pipeline Review, H2 2016 addition with 30 market data tables and 14 figures, spread across 74 pages is available at http://www.rnrmarketresearch.com/treatment-resistant-depression-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Addex Therapeutics Ltd,Amorsa Therapeutics Inc.,Avanir Pharmaceuticals, Inc.,Axsome Therapeutics Inc,Biohaven Pharmaceutical Holding Company Limited,Eli Lilly and Company,Evotec AG,Johnson & Johnson,Otsuka Holdings Co., Ltd.,Relmada Therapeutics, Inc.,Reviva Pharmaceuticals Inc.,Sumitomo Dainippon Pharma Co., Ltd.,Takeda Pharmaceutical Company Limited Inquire before buying  http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748031(This is a premium report price at US$2000 for a single user PDF license).


The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Visceral Pain - Pipeline Review, H2 2016 addition with 25 market data tables and 12 figures, spread across 58 pages http://www.reportsnreports.com/reports/703650-visceral-pain-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis ADX-71441, ADX-71743, ASP-7663, CC-8464, GIC-1002, MED-1101, Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain, NEO-5937, NeuP-12, piromelatine, PR-38, RO-656570, SBFI-26, Small Molecule to Block Nav1.9 Channel for Pain, URB-937 Addex Therapeutics, Astellas Pharma Inc., Chromocell Corporation, GIcare Pharma Inc, Grunenthal GmbH, Medestea Research & Production S.p.A., Neurim Pharmaceuticals Ltd, Pfizer Inc., Inquire before buying for this http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=703650


News Article | November 8, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Psychosis     ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Psychosis     and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Psychosis   - Pipeline Review, H2 2016 addition with  24 market data tables and 11 figures, spread across 70 pages is available at http://www.rnrmarketresearch.com/psychosis-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Acadia Pharmaceuticals Inc.,Addex Therapeutics Ltd,Evotec AG,Gabather AB,Glenmark Pharmaceuticals Ltd.,Heptares Therapeutics Limited,Integrative Research Laboratories Sweden AB,Merck & Co., Inc.,Newron Pharmaceuticals S.p.A.,Reviva Pharmaceuticals Inc.,Sumitomo Dainippon Pharma Co., Ltd.,Sunovion Pharmaceuticals Inc. Inquire before buying, http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748041(This is a premium report price at US$2000 for a single user PDF license).


BOSTON--(BUSINESS WIRE)--PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced the appointment of Bharatt Chowrira, Ph.D., J.D., as the Company’s President and Chief of Business and Strategy. In this new role, Dr. Chowrira will work as a close partner to PureTech’s Chief Executive on strategy, corporate and business development, and value realization across PureTech Health’s pipeline. “We are thrilled to have Bharatt join PureTech Health and bring his diverse experience and deal-making track record to our team as we rapidly approach key value-driving milestones,” said Daphne Zohar, Chief Executive Officer of PureTech Health. “PureTech Health has an all-star team and an exciting, advanced pipeline which I believe has tremendous value. I look forward to working closely with Daphne and other members of this exceptional team and prestigious board to realize some of this value and raise the profile of the company with a broader group of investors and analysts. This is an exciting time to join one of the most innovative companies in healthcare and biotech,” Dr. Chowrira commented. Dr. Chowrira joins PureTech Health with more than two decades of experience in the biopharma industry, combining a unique blend of R&D, corporate development, operations, financing, public offering, M&A, legal, IP, and licensing expertise. Dr. Chowrira was most recently the President of Synlogic, a Cambridge, MA-based biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, where he oversaw and managed corporate and business development, alliance management, financial, HR, IP, and legal operations. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals, which was acquired by Teva Pharmaceuticals in the spring of 2015 for $3.5 billion. Previously, he was President and Chief Executive Officer of Addex Therapeutics, a biotechnology company publicly-traded on the SIX Swiss Exchange. Before that, he held various leadership and management positions at Nektar Therapeutics, Merck & Co., Sirna Therapeutics (acquired by Merck & Co. for $1.1 billion), and Ribozyme Pharmaceuticals. Dr. Chowrira also serves on the board of Critical Outcome Technologies, Inc. He has a J.D. from the University of Denver’s Sturm College of Law, a Ph.D. in Molecular Biology from the University of Vermont College of Medicine, an M.S. in Molecular Biology from Illinois State University, and a B.S. in Microbiology from the UAS, Bangalore, India. About PureTech Health PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical company creating 21st century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We have multiple human proof-of-concept studies and pivotal or registration studies expected to read out in the next two years. PureTech Health’s rich and growing research and development pipeline has been developed in collaboration with some of the world’s leading scientific experts who, along with PureTech's experienced team and board, analyze more than 650 scientific discoveries per year to identify and advance only the opportunities we believe hold the most promise for patients. This team and process place PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter. Forward Looking Statement This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | November 16, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes Disease and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Type 2 Diabetes Disease - Pipeline Review, H2 2016 addition with 249 market data tables and 17 figures, spread across 1298 pages is available at http://www.reportsnreports.com/reports/747717-type-2-diabetes-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Addex Therapeutics Ltd, Adocia ,Advinus Therapeutics Ltd ,Aegis Therapeutics, LLC ,AFFiRiS AG Alize Pharma SAS ,AlphaMab Co., Ltd ,Alteogen Inc. ,Amarantus Bioscience Holdings, Inc. ,Ambrx, Inc. ,Amgen Inc. ,Anchor Therapeutics, Inc. ,AntriaBio, Inc. ,Aphios Corporation ,APT Therapeutics, Inc. ,Araim Pharmaceuticals, Inc. ,Arisaph Pharmaceuticals, Inc. ,ArisGen SA ,Artery Therapeutics, Inc. ,Astellas Pharma Inc. ,AstraZeneca Plc ,Aus Bio Ltd ,Bayer AG ,Beta-Cell NV ,Betagenon AB,Biocon Limited ,Biodel Inc. ,Biogenomics Limited ,BioLingus AG ,BioRestorative Therapies, Inc. BioTherapeutics Inc. ,Biscayne Pharmaceuticals, Inc. ,Boehringer Ingelheim GmbH Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=747717(This is a premium report price at US$2000 for a single user PDF license).

Loading Addex Therapeutics collaborators
Loading Addex Therapeutics collaborators